Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pomalidomide + Low-dose Dexamethasone in Chinese RRMM
NCT02916420Phase 3Unknown
- Sponsor
- Simcere Pharmaceutical Group
- Start
- Sep 2016
- Primary completion
- Jun 2018
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of pomalidomide in multiple myeloma (MM), sponsored by Simcere Pharmaceutical Group. Primary endpoint: Objective Response Rate up to 2 years. Status: unknown.
02
Drugs
pomalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02916420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02916420.